Common: Insomnia, decreased appetite, weight loss, dry mouth
Serious: Cardiovascular events, psychiatric symptoms, growth suppression in childre
---
### **Monitoring / Labs**
- **Cardiovascular**: Baseline and routine monitoring of heart rate and blood pressure.
- **Growth in Pediatrics**: Regular monitoring of height and weight to detect growth suppression.
- **Psychiatric Symptoms**: Observe for mood changes, anxiety, or psychosis.
- **Abuse Potential**: Monitor for misuse or diversion.
---
### **Education**
- **When to Call the Doctor:**
- Severe **mood changes, aggression, or suicidal thoughts**.
- Chest pain, rapid heartbeat, shortness of breath (**cardiovascular concerns**).
- Uncontrolled movements, tics, or worsening anxiety.
- Numbness, coldness, or color changes in fingers or toes (**circulatory issues**).
- Unexplained weight loss or **delayed growth in pediatric patients**.
- **Safety Tips:**
- **Monitor blood pressure and heart rate**, especially in patients with cardiovascular risk.
- Use caution in patients with **anxiety, bipolar disorder, or psychosis**, as symptoms may worsen.
- Avoid **caffeine and other stimulants**, which may amplify side effects.
- Ensure **adequate hydration and nutrition**, as appetite suppression is common.
- **Tapering may be required** if discontinuing after long-term use.
- **Parent Tips for Pediatric Patients:**
- **Encourage a nutrient-dense diet** to counteract appetite suppression.
- Administer in the **morning before school** for optimal effect.
- Monitor **school performance and behavioral changes**.
- Observe for **sleep disturbances**; adjust timing if necessary.
- Communicate regularly with **teachers and caregivers** about medication effects.
---
### **Additional Information**
- **Contraindications:**
- **Hypersensitivity** to amphetamines or formulation components.
- **Use within 14 days of MAOI therapy** (risk of hypertensive crisis).
- Symptomatic **cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma**.
- **History of substance use disorder**, unless benefits outweigh risks.
- **Pregnancy:**
- **Category C**; use only if benefits outweigh risks.
- May cause **neonatal withdrawal symptoms** or **low birth weight**.
- **Lactation:**
- **Excreted in breast milk**; **not recommended** due to potential infant exposure.
- **Drug Interactions:**
- **Serotonergic drugs** (e.g., SSRIs, SNRIs, MAOIs) increase **serotonin syndrome risk**.
- **Acidifying agents** (e.g., ascorbic acid) may reduce drug absorption.
- **Alkalinizing agents** (e.g., sodium bicarbonate) may increase amphetamine levels.
- May potentiate **hypertensive effects** of certain medications (e.g., decongestants, beta-agonists).